|
SERPINE1
|
Plasminogen Activator Inhibitor-1 Deficiency
|
0.700 |
GermlineCausalMutation |
ORPHANET |
Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene.
|
9207454 |
1997 |
|
SERPINE1
|
Plasminogen Activator Inhibitor-1 Deficiency
|
0.700 |
Biomarker |
CTD_human |
|
|
|
|
SERPINE1
|
Plasminogen Activator Inhibitor-1 Deficiency
|
0.700 |
Biomarker |
GENOMICS_ENGLAND |
|
|
|
|
SERPINE1
|
Hypertensive disease
|
0.600 |
Biomarker |
CTD_human |
Vascular and thrombogenic effects of pulmonary exposure to Libby amphibole.
|
22352330 |
2012 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
Biomarker |
CTD_human |
Fosinopril and valsartan intervention in gene expression of Klotho, MMP-9, TIMP-1, and PAI-1 in the kidney of spontaneously hypertensive rats.
|
21051829 |
2010 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
Biomarker |
CTD_human |
Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
|
18682491 |
2009 |
|
SERPINE1
|
Kidney Failure, Chronic
|
0.510 |
Biomarker |
CTD_human |
Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure.
|
19420110 |
2009 |
|
SERPINE1
|
Focal glomerulosclerosis
|
0.500 |
Biomarker |
CTD_human |
Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
|
18682491 |
2009 |
|
SERPINE1
|
Obesity
|
0.400 |
Biomarker |
CTD_human |
Together, resveratrol can act as NF κ B inhibitor in adipocytes and thus the subsequently reduced PAI-1 expression in inflamed adipose tissue might provide a new insight towards novel treatment options of obesity.
|
23819014 |
2013 |
|
SERPINE1
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker |
CTD_human |
Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray.
|
16367923 |
2006 |
|
SERPINE1
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker |
CTD_human |
Nucleotide variations in genes encoding plasminogen activator inhibitor-2 and serine proteinase inhibitor B10 associated with prostate cancer.
|
16172807 |
2005 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
Biomarker |
CTD_human |
Atheroprotective Mechanisms Activated by Fluid Shear Stress in Endothelial Cells.
|
12677255 |
2002 |
|
SERPINE1
|
Congestive heart failure
|
0.360 |
Biomarker |
CTD_human |
Vascular and thrombogenic effects of pulmonary exposure to Libby amphibole.
|
22352330 |
2012 |
|
SERPINE1
|
Liver neoplasms
|
0.360 |
Biomarker |
CTD_human |
Loss of metallothionein predisposes mice to diethylnitrosamine-induced hepatocarcinogenesis by activating NF-kappaB target genes.
|
21159647 |
2010 |
|
SERPINE1
|
Fatty Liver
|
0.350 |
Biomarker |
CTD_human |
Liver Disease in a Residential Cohort With Elevated Polychlorinated Biphenyl Exposures.
|
29684222 |
2018 |
|
SERPINE1
|
Steatohepatitis
|
0.350 |
Biomarker |
CTD_human |
Liver Disease in a Residential Cohort With Elevated Polychlorinated Biphenyl Exposures.
|
29684222 |
2018 |
|
SERPINE1
|
Heart failure
|
0.350 |
Biomarker |
CTD_human |
Vascular and thrombogenic effects of pulmonary exposure to Libby amphibole.
|
22352330 |
2012 |
|
SERPINE1
|
Fatty Liver
|
0.350 |
Biomarker |
CTD_human |
Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake.
|
18641190 |
2008 |
|
SERPINE1
|
Major Depressive Disorder
|
0.350 |
Biomarker |
PSYGENET |
Our findings show, for the first time, that SERPINE1 genetic variants may play a role in MDD susceptibility and in the acute therapeutic response to selective serotonin reuptake inhibitors.
|
18794724 |
2008 |
|
SERPINE1
|
Steatohepatitis
|
0.350 |
Biomarker |
CTD_human |
Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake.
|
18641190 |
2008 |
|
SERPINE1
|
Thrombosis
|
0.340 |
Biomarker |
CTD_human |
Aorta mRNA expression for biomarkers of oxidative stress (HO-1, LOX-1), inflammation (MIP-2), and thrombosis (tPA, PAI-1, vWf) were increased at baseline in SH and SHHF relative to WKY.
|
22352330 |
2012 |
|
SERPINE1
|
Thrombosis
|
0.340 |
Biomarker |
CTD_human |
Well characterized atheroprotective mechanisms include inhibition of thrombosis (increased tissue-type plasminogen activator and decreased plasminogen activator inhibitor-1), inhibition of endothelial cell apoptosis, limitation of permeability (uptake of low-density lipoprotein), prevention of white blood cell binding and transmigration (no expression of adhesion molecules such as intercellular adhesion molecule-1 [ICAM-1] and vascular cell adhesion molecule-1 [VCAM-1] and no release of monocyte chemotactic protein-1) and increased bioavailability of nitric oxide (because of increased expression of endothelial nitric oxide synthase and manganese superoxide dismutase).
|
12677255 |
2002 |
|
SERPINE1
|
Pre-Eclampsia
|
0.330 |
Biomarker |
CTD_human |
Supporting previous reports, the expression of sFlt-1 and PAI-1 were also upregulated in PE placentas.
|
18679377 |
2008 |
|
SERPINE1
|
Ureteral obstruction
|
0.320 |
Biomarker |
CTD_human |
The antihelmenthic phosphate niclosamide impedes renal fibrosis by inhibiting homeodomain-interacting protein kinase 2 expression.
|
28318631 |
2017 |
|
SERPINE1
|
Depressive Symptoms
|
0.320 |
Biomarker |
PSYGENET |
Our preliminary results suggest that the SERPINE1 promoter polymorphisms may be associated with antidepressant treatment, but not with the increased susceptibility to the depressive symptoms in AD.
|
22503724 |
2012 |